Isosorbide-5-mononitrate significantly decreased carotid-femoral pulse wave velocity at 2 and 4 weeks compared to baseline (p<0.05) in patients with essential hypertension.
Does isosorbide-5-mononitrate improve large artery distensibility in patients with essential hypertension?
Isosorbide-5-mononitrate added to standard therapy improves large arterial distensibility in hypertensive patients independent of blood pressure changes.
p-value: p=<0.05
To evaluate the clinical efficacy of long-acting nitrates, isosorbide-5-mononitrate (IS-5-MN), on large artery distensibility in patients with essential hypertension. Large arterial distensibility was assessed by automatic noninvasive measurement of the carotid-femoral pulse wave velocity (PWV). Seventeen patients aged 62.53+/-7.94 years (mean+/-SD) with essential hypertension undering long-term antihypertensive therapy were studied in this trial. PWV was measured 2 weeks and 4 weeks after oral administration of IS-5-MN (30 mg once daily) with previous therapy. There was no significant difference in systolic blood pressure, diastolic blood pressure, pulse pressure or heart rate at 2 weeks and 4 weeks after treatment compared with baseline. The carotid-femoral PWV decreased significantly at 2 and 4 weeks after treatment (p<0.05, p< 0.05, respectively). Long-acting nitrates have potential value in improving large arterial distensibility in patients with essential hypertension independent of blood pressure alteration. It might be used as an effectively additive drug in hypertension control.
Wang et al. (Mon,) conducted a other in essential hypertension (n=17). isosorbide-5-mononitrate (IS-5-MN) vs. baseline was evaluated on carotid-femoral pulse wave velocity (PWV) (p=<0.05). Isosorbide-5-mononitrate significantly decreased carotid-femoral pulse wave velocity at 2 and 4 weeks compared to baseline (p<0.05) in patients with essential hypertension.